MyAverix Finance
SHE · Healthcare
R&G PharmaStudies Co. Ltd. A (301333)
Biotechnology
R&G PharmaStudies Co. Ltd. A (301333) is listed on SHE in the Healthcare sector. Industry: Biotechnology. As of 2026-03-29, reported market cap is $6.00B, P/E ratio is 39.08, net margin is 19.2%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 301333
R&G PharmaStudies Co. Ltd. A (301333) — FAQ
What is R&G PharmaStudies Co. Ltd. A's market cap?
R&G PharmaStudies Co. Ltd. A (301333) has a reported market cap of $6.00B (data as of 2026-03-29).
What is 301333's P/E ratio?
The price-to-earnings (P/E) ratio for R&G PharmaStudies Co. Ltd. A (301333) is 39.08 (data as of 2026-03-29).
Does R&G PharmaStudies Co. Ltd. A pay a dividend?
Dividend yield is not available in the current snapshot for R&G PharmaStudies Co. Ltd. A (301333). Check the MyAverix Finance app for the latest dividend data.
What sector is R&G PharmaStudies Co. Ltd. A in?
R&G PharmaStudies Co. Ltd. A (301333) is classified in the Healthcare sector (Biotechnology industry).
What exchange is 301333 listed on?
301333 is listed on SHE.
What is R&G PharmaStudies Co. Ltd. A's net margin?
R&G PharmaStudies Co. Ltd. A (301333) reports a net margin of 19.2% (data as of 2026-03-29).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.